MaxCyte, Inc. (LON:MXCT – Get Free Report)’s stock price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 322.33 ($4.16) and traded as low as GBX 242 ($3.12). MaxCyte shares last traded at GBX 243.10 ($3.14), with a volume of 9,254 shares trading hands.
MaxCyte Stock Performance
The stock’s 50 day moving average price is GBX 320.49 and its 200 day moving average price is GBX 306.95. The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81. The company has a market capitalization of £337.93 million, a P/E ratio of -9.38 and a beta of 1.13.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Stories
- Five stocks we like better than MaxCyte
- Investing in the High PE Growth Stocks
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- What is the Nasdaq? Complete Overview with History
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Quiet Period Expirations Explained
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
